Pfizer acquires rights to terguride

NEW YORK Pfizer will acquire worldwide rights to a drug for treating pulmonary arterial hypertension, the drug maker said Wednesday.

Pfizer announced it would acquire terguride, an investigational drug, from Germany-based Ergonex Pharma. Under the agreement, Pfizer will support completion of phase 2 clinical trials of the drug and have exclusive worldwide rights to commercialize the drug, except in Japan. Ergonex will receive milestone and royalty payments.

“Pfizer’s unique business unit structure positions us to advance a broad portfolio of innovative research programs designed to lead to a diversity of products, including highly specialized ones in disease areas like PAH,” Pfizer specialty care business unit president Geno Germano said. “In the case of terguride, we are pleased that we can support its continued development given our commitment to advancing science in PAH and to bring new, potentially disease-modifying treatments to patients.”